Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Bangerter

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Acta Cytologica|August 25, 2009
Cytomorphologic pitfall of primary malignant melanoma of the parotid gland: a case reportMarkus Bangerter
MMW Fortschritte Der Medizin|July 4, 2016
[Not Available]Markus Bangerter, Roland M Schmid
MMW Fortschritte Der Medizin|August 21, 2015
[Chemotherapy is better than its reputation: important developments within the last decades]Bernhard Heinrich, Olaf Brudler, Markus Bangerter
Acta Cytologica|June 1, 2007
Fine needle aspiration cytology and flow cytometry in the diagnosis and subclassification of non-Hodgkin's lymphoma based on the World Health Organization classificationMarkus Bangerter, Olaf Brudler, Bernhard Heinrich, et al.
Acta Cytologica|March 8, 2008
Open or closed nuclear membrane? A question to help distinguish malignant lymphoma from carcinoma and sarcomaMarkus Bangerter, Olaf Brudler, Bernhard Heinrich, et al.
Cancer Research|May 17, 2003
3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human diseaseMartin Wagner, Ulrike Seitz, Andreas Buck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemiaAlexander Kröber, Johannes Bloehdorn, Sebastian Hafner, et al.
BMC Cancer|August 25, 2011
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trialClemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Acta Cytologica|August 25, 2009
Cytomorphologic pitfall of primary malignant melanoma of the parotid gland: a case reportMarkus Bangerter
MMW Fortschritte Der Medizin|July 4, 2016
[Not Available]Markus Bangerter, Roland M Schmid
MMW Fortschritte Der Medizin|August 21, 2015
[Chemotherapy is better than its reputation: important developments within the last decades]Bernhard Heinrich, Olaf Brudler, Markus Bangerter
Acta Cytologica|June 1, 2007
Fine needle aspiration cytology and flow cytometry in the diagnosis and subclassification of non-Hodgkin's lymphoma based on the World Health Organization classificationMarkus Bangerter, Olaf Brudler, Bernhard Heinrich, et al.
Acta Cytologica|March 8, 2008
Open or closed nuclear membrane? A question to help distinguish malignant lymphoma from carcinoma and sarcomaMarkus Bangerter, Olaf Brudler, Bernhard Heinrich, et al.
Cancer Research|May 17, 2003
3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human diseaseMartin Wagner, Ulrike Seitz, Andreas Buck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemiaAlexander Kröber, Johannes Bloehdorn, Sebastian Hafner, et al.
BMC Cancer|August 25, 2011
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trialClemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, et al.
Pageof 1